University of Pittsburgh researchers have developed a new therapeutic approach for inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. Despite current treatments, many IBD patients do not respond or lose effectiveness over time, and the medications often have significant side effects. The researchers present an orally delivered, targeted microparticle formulation that aims to specifically address active inflammation in IBD. This innovative approach could revolutionize the treatment of IBD, which affects more than 1.5 million people in the United States alone.